Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.

Acta medica Indonesiana

Volumn 44, Issue 1, 2012, Pages 16-22

  Ziaee, Amir ^a   Oveisi, Sonia ^b   Abedini, Atefeh ^b   Hashemipour, Sima ^b   Karimzadeh, Toktam ^b   Ghorbani, Azam ^b  

^a QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CHOLESTEROL; INSULIN; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; RISK; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84864301691     PISSN: 01259326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)